Literature DB >> 33779306

Liver glycogen-induced enhancements in hypoglycemic counterregulation require neuroglucopenia.

Shana O Warner1, Abby M Wadian1, Marta Smith2, Ben Farmer2, Yufei Dai1, Nicole Sheanon3, Dale S Edgerton2, Jason J Winnick1.   

Abstract

Iatrogenic hypoglycemia is a prominent barrier to achieving optimal glycemic control in patients with diabetes, in part due to dampened counterregulatory hormone responses. It has been demonstrated that elevated liver glycogen content can enhance these hormonal responses through signaling to the brain via afferent nerves, but the role that hypoglycemia in the brain plays in this liver glycogen effect remains unclear. During the first 4 h of each study, the liver glycogen content of dogs was increased by using an intraportal infusion of fructose to stimulate hepatic glucose uptake (HG; n = 13), or glycogen was maintained near fasting levels with a saline infusion (NG; n = 6). After a 2-h control period, during which the fructose/saline infusion was discontinued, insulin was infused intravenously for an additional 2 h to bring about systemic hypoglycemia in all animals, whereas brain euglycemia was maintained in a subset of the HG group by infusing glucose bilaterally into the carotid and vertebral arteries (HG-HeadEu; n = 7). Liver glycogen content was markedly elevated in the two HG groups (43 ± 4, 73 ± 3, and 75 ± 7 mg/g in NG, HG, and HG-HeadEu, respectively). During the hypoglycemic period, arterial plasma glucose levels were indistinguishable between groups (53 ± 2, 52 ± 1, and 51 ± 1 mg/dL, respectively), but jugular vein glucose levels were kept euglycemic (88 ± 5 mg/dL) only in the HG-HeadEu group. Glucagon and epinephrine responses to hypoglycemia were higher in HG compared with NG, whereas despite the increase in liver glycogen, neither increased above basal in HG-HeadEu. These data demonstrate that the enhanced counterregulatory hormone secretion that accompanies increased liver glycogen content requires hypoglycemia in the brain.NEW & NOTEWORTHY It is well known that iatrogenic hypoglycemia is a barrier to optimal glycemic regulation in patients with diabetes. Our data confirm that increasing liver glycogen content 75% above fasting levels enhances hormonal responses to insulin-induced hypoglycemia and demonstrate that this enhanced hormonal response does not occur in the absence of hypoglycemia in the brain. These data demonstrate that information from the liver regarding glycogen availability is integrated in the brain to optimize the counterregulatory response.

Entities:  

Keywords:  glucagon; gut amino acid production; hepatic glucose metabolism; type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33779306      PMCID: PMC8424545          DOI: 10.1152/ajpendo.00501.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  52 in total

Review 1.  Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes.

Authors:  Philip E Cryer
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

2.  Defective activation of skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia.

Authors:  Staffan Enoksson; Sonia K Caprio; Frances Rife; Gerald I Shulman; William V Tamborlane; Robert S Sherwin
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

3.  Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis.

Authors:  Jason J Winnick; Guillaume Kraft; Justin M Gregory; Dale S Edgerton; Phillip Williams; Ian A Hajizadeh; Maahum Z Kamal; Marta Smith; Ben Farmer; Melanie Scott; Doss Neal; E Patrick Donahue; Eric Allen; Alan D Cherrington
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

4.  Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man.

Authors:  J Gerich; J Davis; M Lorenzi; R Rizza; N Bohannon; J Karam; S Lewis; R Kaplan; T Schultz; P Cryer
Journal:  Am J Physiol       Date:  1979-04

5.  Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs.

Authors:  Noelia Rivera; Christopher J Ramnanan; Zhibo An; Tiffany Farmer; Marta Smith; Ben Farmer; Jose M Irimia; Wanda Snead; Margaret Lautz; Peter J Roach; Alan D Cherrington
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

6.  Novel glucosensor for hypoglycemic detection localized to the portal vein.

Authors:  A L Hevener; R N Bergman; C M Donovan
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

7.  Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans.

Authors:  C Fanelli; S Calderone; L Epifano; A De Vincenzo; F Modarelli; S Pampanelli; G Perriello; P De Feo; P Brunetti; J E Gerich
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans.

Authors:  P J Boyle; J C Scott; A J Krentz; R J Nagy; E Comstock; C Hoffman
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.

Authors:  J H Hwang; G Perseghin; D L Rothman; G W Cline; I Magnusson; K F Petersen; G I Shulman
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

Review 10.  The barrier of hypoglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Diabetes       Date:  2008-12       Impact factor: 9.461

View more
  1 in total

1.  C-peptide enhances glucagon secretion in response to hyperinsulinemia under euglycemic and hypoglycemic conditions.

Authors:  Mary Courtney Moore; Shana O Warner; Yufei Dai; Nicole Sheanon; Marta Smith; Ben Farmer; Rebecca L Cason; Alan D Cherrington; Jason J Winnick
Journal:  JCI Insight       Date:  2021-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.